Summit Therapeutics Plans Global Phase III HARMONi-10 Trial of Ivonescimab

Summit Therapeutics (SMMT) plans a global Phase III trial (HARMONi-10) for ivonescimab vs. durvalumab in treating unresectable Stage III non-small cell lung cancer. The trial, set to begin in Q4 2026, aims to study patients without disease progression after initial treatment, with progression-free survival as the primary endpoint. This is Summit's sixth Phase III ivonescimab study and fourth in this cancer type, according to the company.

Original reporting
Published Nov 18, 2026, 1:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 1:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Summit Therapeutics Plans Global Phase III HARMONi-10 Trial of Ivonescimab — source image
Decision brief

The 30-second read

$SMMTBullishMed
01

Why it matters

A new global Phase III trial with a defined comparator and primary endpoint can shift expectations for the program’s probability of success, but the near-term tradable catalyst is limited because site activations are not until Q4 2026.

02

Market read

This is a pipeline-development headline that can support biotech sentiment, but it is not a near-term earnings or regulatory catalyst.

03

What to watch

Key execution risks remain unaddressed here, including enrollment pace, event rate for progression-free survival, and how ivonescimab’s efficacy compares in practice versus durvalumab.

Relevance 7/10Novelty 7/10Timing: trial site activations expected to begin in Q4 2026

Background

Summit is advancing ivonescimab in unresectable Stage III non-small cell lung cancer after no progression following platinum-based concurrent chemoradiation.

Company-level read

Ticker impact

$SMMTBullishMedium confidence
Context

Summit Therapeutics announced a global Phase III HARMONi-10 trial for ivonescimab in unresectable Stage III NSCLC, with PFS as the primary endpoint.

Expected impact

Likely modest upside bias as investors price in progress toward Phase III readouts, tempered by the long lead time to site activations and results.

Evidence & confidence

The article discloses a new Phase III plan (global, comparator durvalumab, PFS endpoint) and expected Q4 2026 site activations, which can improve perceived pipeline credibility even without interim data.

Market effects

Reinforces competitive intensity in consolidation therapy for unresectable Stage III NSCLC and highlights ivonescimab’s positioning versus durvalumab.

No direct regional market linkage beyond US-listed biotech sentiment.

Global trial scope may attract broader investor attention to oncology development timelines and trial execution risk.

Counterpoint

Phase III plans can fail or face enrollment and regulatory hurdles; without data, the market may discount the announcement quickly.

Key entities

  • Summit Therapeutics

    Sponsor of the HARMONi-10 global Phase III trial of ivonescimab.

  • ivonescimab

    Summit’s investigational therapy being tested as consolidation therapy.

  • durvalumab

    Established therapy used as the comparator arm in HARMONi-10.

  • HARMONi-10

    Global Phase III trial design, primary endpoint progression-free survival, expected site activations in Q4 2026.

Related articles

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$SMMTMed

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung…

Summit Therapeutics Inc. (SMMT) filed an SEC Form 8-K — Other Events. Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer Global Registration-Enabling Study to Evaluate Ivonescimab Versus Durvalumab as Consolidation Therapy Following Concurre

$SMMTMedAI 8/10

Summit starts phase 3 trial of ivonescimab in lung cancer

Summit Therapeutics (NASDAQ: SMMT) launched a Phase III trial (HARMONi-10) for ivonescimab in lung cancer, comparing it to durvalumab. The trial aims to evaluate progression-free survival as the primary endpoint, with global site activations expected in Q4 2026. Ivonescimab, a PD-1 x VEGF bispecific antibody, is not approved in the U.S. or Europe but has marketing authorization in China. Over 5,000 patients have been treated in clinical studies globally, and over 100,000 in China.